Celldex Therapeutics (CLDX) Profit After Tax (2010 - 2026)

Celldex Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$79.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 48.32% year-over-year to -$79.8 million in Q1 2026; TTM through Mar 2026 was -$285.2 million, a 59.47% decrease from a year earlier, with the FY2025 full-year figure at -$258.8 million, down 63.92% from the prior year.
• Profit After Tax rose to -$79.8 million in Q1 2026 per CLDX's latest filing, from -$81.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$24.8 million in Q1 2022 and bottomed at -$81.8 million in Q4 2025.
• The 5-year median for Profit After Tax is -$38.2 million (2023), against an average of -$44.1 million.
• Across the five-year window, Profit After Tax tumbled 173.29% in 2022 and advanced 16.37% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$25.1 million in 2022, then sank by 67.76% to -$42.1 million in 2023, then slipped by 11.76% to -$47.1 million in 2024, then plunged by 73.66% to -$81.8 million in 2025, then gained by 2.42% to -$79.8 million in 2026.
• Per Business Quant, the three latest CLDX Profit After Tax figures stand at -$79.8 million (Q1 2026), -$81.8 million (Q4 2025), and -$67.0 million (Q3 2025).